{"groups":[{"description":"Orca-T administered after myeloablative conditioning followed by single-agent tacrolimus","id":"FG000","title":"Orca-T"},{"description":"Unmanipulated allograft from peripheral blood of a matched donor after myeloablative conditioning followed by tacrolimus and methotrexate","id":"FG001","title":"Standard of Care"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"9"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"9"}],"type":"Progression/Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received Standard of Care"},{"reasons":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"64"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"93"},{"groupId":"FG001","numSubjects":"94"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"94"}],"type":"Participants Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"93"},{"groupId":"FG001","numSubjects":"92"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"187 participants were randomized to treatment from 19 study centers, of which 182 participants were treated"}